Suven Life Sciences Ltd.

•

suven.comBSE: 530239NSE: SUVEN

Market Cap₹ 10,472 Cr.

Current Price

High / Low₹ 403 / 124

Stock P/E0.0

Book Value₹ 56

Price to Book2.60

Dividend Yield0.00 %

ROCE-4.7 %

ROE-5.1 %

Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2019 • Manufacturing (CRAMS): 89.3% • Services (DDDSS): 7.3% • Unallocated: 3.5%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company is almost debt free
Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.25x)
Institutional investors have been accumulating - FII+DII up 2.9pp

CONS

Company is loss-making at the operating / net level
Operating cash flow has been negative in recent years
Interest coverage is weak at -210.7x - earnings barely cover interest
Company has a low return on capital employed of -3.8%
Company has a low return on equity of -3.9% over last 3 years
Company's sales have been declining over the last five years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY 50 NIFTY 500 NIFTY LARGEMIDCAP 250 NIFTY 100 NIFTY 200

S.No.	Name
1.	SUNPHARMA	1881.10	37.31	451338.90	0.85	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9570.55	86.86	254068.03	0.31	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4962.75	86.55	188767.06	0.77	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1150.00	25.42	114712.94	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1383.95	33.17	111803.57	0.94	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1945.50	96.14	105117.74	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	AUROPHARMA	1686.00	26.13	97008.71	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
8.	LUPIN	2112.00	17.47	96574.55	0.85	1416.98	16.01	8276.89	34.28	28.86	29.59
9.	DRREDDY	1151.50	29.83	96113.39	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
10.	MANKIND	2305.85	46.63	95242.00	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2477.35	38.89	69916.93	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	SUVEN	370.60	0.00	10471.77	0.00	-127.61	-147.70	3.57	90.70	-78.71	-3715.76

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	4	3	2	2	1	3	2	1	2	1	3	2	4
	11	11	12	9	11	16	15	16	16	19	18	18	27
Operating Profit	-7	-8	-9	-7	-10	-14	-13	-15	-14	-18	-15	-16	-24
OPM %	-178.68%	-264.05%	-375.51%	-287.45%	-998.02%	-530.74%	-826.09%	-1014.29%	-748.66%	-1946.74%	-529.89%	-1066.45%	-662.98%
	6	13	6	4	4	4	2	1	1	4	3	7	8
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	2	2	2	2	1	1	2	1	1	1	1	2	2
Profit before Tax	-3	3	-5	-4	-8	-11	-13	-15	-15	-15	-13	-11	-16
Tax %	-0.00%	0.00%	-0.00%	24.21%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%
Net Profit	-3	3	-5	-3	-8	-11	-13	-15	-15	-15	-13	-11	-16
	-0.13	13.00	-0.22	-0.14	-0.35	-0.51	-0.61	-0.69	-0.68	-0.70	-0.60	-0.50	-0.61

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	544	625	286	14	13	12	14	12	7	7	9
	378	392	237	50	44	48	41	43	58	70	81
Operating Profit	165	233	49	-35	-30	-37	-28	-31	-52	-63	-73
OPM %	30.42%	37.25%	17.05%	-244.63%	-225.92%	-308.41%	-204.13%	-263.87%	-778.81%	-884.09%	-824.09%
	21	23	27	14	8	5	14	29	11	14	21
Interest	6	5	2	1	1	1	0	0	0	0	1
Depreciation	21	21	11	4	4	4	7	7	6	6	6
Profit before Tax	159	230	63	-26	-28	-36	-20	-9	-47	-55	-56
Tax %	22.52%	31.20%	38.04%	46.97%	19.04%	-0.00%	-0.00%	11.12%	-0.00%	-0.00%	-0.00%
Net Profit	123	158	39	-14	-23	-36	-20	-8	-47	-55	-56
EPS	9.69	12.45	3.08	-1.08	-1.78	-2.69	-1.13	-0.37	-2.16	-2.08	—
Dividend Payout %	10.31%	12.05%	48.71%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	—

COMPOUNDED SALES GROWTH

10 Years:: -35%
5 Years:: -12%
3 Years:: -19%

COMPOUNDED PROFIT GROWTH

10 Years:: —
5 Years:: —
3 Years:: —

STOCK PRICE CAGR

10 Years:: 7%
5 Years:: 35%
3 Years:: 76%
1 Year:: 61%

RETURN ON EQUITY

10 Years:: 1%
5 Years:: -5%
3 Years:: -4%
Last Year:: -5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	13	13	13	13	13	15	22	22	22	26
	719	854	389	375	352	461	832	824	776	1,320
	72	34	3	4	3	2	1	0	0	12
Trade Payables	38	57	7	6	3	2	2	2	5	5
	122	161	145	105	139	101	99	4	5	168
Total Liabilities	964	1,119	557	503	509	580	954	851	809	1,531
	306	308	22	25	21	38	37	28	60	73
Capital Work in Progress	10	25	0	0	5	4	0	0	0	4
	366	381	359	242	295	426	528	653	714	1,093
	93	139	0	0	0	0	0	1	0	0
	0	0	0	0	0	0	0	1	1	2
Cash & Bank	5	21	0	1	39	3	174	153	20	331
	185	244	175	236	150	110	215	15	14	28
Total Assets	964	1,119	557	503	509	580	954	851	809	1,531

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	182	148	3	-42	-36	-36	-22	-21	-47	-69
Cash from Investing	-353	-38	3	42	2	-107	-349	-1	44	-686
Cash from Financing	-30	-52	5	4	35	146	396	-1	-1	757
	-236	15	-4	1	1	2	24	-22	-4	2

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	70.27	70.27	70.27	70.27	70.27	67.36	67.36	70.15	70.08
	0.45	0.33	0.34	0.25	0.58	1.17	1.07	0.91	0.56
	1.05	1.05	1.05	0.01	0.02	3.39	3.39	4.62	2.93
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	28.23	28.34	28.34	29.47	29.13	28.07	28.18	24.32	26.43

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-03

Press Release

2026-09-03 - Suven Life Sciences Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Suven Life Sciences Announces Completion of Patient Enrollment in Global Phase-3 Study of Masupirdine (SUVN-502) for Agitation Associated with Alzheimer s Dementia (AAD)".

2026-08-25

Shareholders meeting

2026-08-25 - Suven Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 25, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

2026-08-11

Monitoring Agency Report

2026-08-11 - Monitoring Agency Report for the quarter ended June 30, 2026

2026-08-07

Copy of Newspaper Publication

2026-08-07 - Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-06

Outcome of Board Meeting

2026-08-06 - Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

2026-07-31

Copy of Newspaper Publication

2026-07-31 - Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication

2026-07-30

General Updates

2026-07-30 - Suven Life Sciences Limited has informed the Exchange about Letter to Shareholders regarding Annual Report 2025-26

2026-07-30

General Updates

2026-07-30 - Suven Life Sciences Limited has informed the Exchange about Business Responsibility and Sustainability Report for F.Y 2025-26

2026-07-30

Shareholders meeting

2026-07-30 - Suven Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 25, 2026

News

Recent coverage and analyst commentary for SUVEN

Loading news…

🤖

AI Stock Analyst

Suven Life Sciences Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

SUNPHARMA

1881.10

37.31

451338.90

0.85

2901.23

26.53

15299.88

10.98

19.11

28.81

DIVISLAB

9570.55

86.86

254068.03

0.31

902.00

65.50

3080.00

27.80

21.51

40.75

TORNTPHARM

4962.75

86.55

188767.06

0.77

566.00

3.28

4921.00

57.32

19.27

33.81

ZYDUSLIFE

1150.00

25.42

114712.94

0.09

990.20

-34.90

8017.00

23.97

21.39

24.54

CIPLA

1383.95

33.17

111803.57

0.94

785.55

-39.18

7119.28

4.13

16.00

16.73

LAURUSLABS

1945.50

96.14

105117.74

0.10

362.07

123.94

2026.31

29.10

18.20

31.50

AUROPHARMA

1686.00

26.13

97008.71

0.24

1032.03

25.22

9150.35

17.44

12.76

20.54

LUPIN

2112.00

17.47

96574.55

0.85

1416.98

16.01

8276.89

34.28

28.86

29.59

DRREDDY

1151.50

29.83

96113.39

0.69

435.60

-69.10

8099.80

-5.21

13.75

10.63

MANKIND

2305.85

46.63

95242.00

0.04

574.09

29.12

4030.59

12.89

13.24

26.30

GLENMARK

2477.35

38.89

69916.93

0.10

482.83

927.88

4018.48

31.35

20.35

20.03

SUVEN

370.60

0.00

10471.77

0.00

-127.61

-147.70

3.57

90.70

-78.71

-3715.76

Jun 2023

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

Operating Profit

-7

-8

-9

-7

-10

-14

-13

-15

-14

-18

-15

-16

-24

OPM %

-178.68%

-264.05%

-375.51%

-287.45%

-998.02%

-530.74%

-826.09%

-1014.29%

-748.66%

-1946.74%

-529.89%

-1066.45%

-662.98%

Interest

Depreciation

Profit before Tax

-3

-5

-4

-8

-11

-13

-15

-13

-11

-16

Tax %

-0.00%

0.00%

-0.00%

24.21%

-0.00%

Net Profit

-3

-5

-3

-8

-11

-13

-15

-13

-11

-16

-0.13

13.00

-0.22

-0.14

-0.35

-0.51

-0.61

-0.69

-0.68

-0.70

-0.60

-0.50

-0.61

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

TTM

544

625

286

378

392

237

Operating Profit

165

233

-35

-30

-37

-28

-31

-52

-63

-73

OPM %

30.42%

37.25%

17.05%

-244.63%

-225.92%

-308.41%

-204.13%

-263.87%

-778.81%

-884.09%

-824.09%

Interest

Depreciation

Profit before Tax

159

230

-26

-28

-36

-20

-9

-47

-55

-56

Tax %

22.52%

31.20%

38.04%

46.97%

19.04%

-0.00%

11.12%

-0.00%

Net Profit

123

158

-14

-23

-36

-20

-8

-47

-55

-56

EPS

9.69

12.45

3.08

-1.08

-1.78

-2.69

-1.13

-0.37

-2.16

-2.08

—

Dividend Payout %

10.31%

12.05%

48.71%

0.00%

—

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Equity Capital

719

854

389

375

352

461

832

824

776

1,320

Trade Payables

122

161

145

105

139

101

168

Total Liabilities

964

1,119

557

503

509

580

954

851

809

1,531

306

308

Capital Work in Progress

366

381

359

242

295

426

528

653

714

1,093

139

Cash & Bank

174

153

331

185

244

175

236

150

110

215

Total Assets

964

1,119

557

503

509

580

954

851

809

1,531

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

182

148

-42

-36

-22

-21

-47

-69

Cash from Investing

-353

-38

-107

-349

-1

-686

Cash from Financing

-30

-52

146

396

-1

757

-236

-4

-22

-4

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

70.27

67.36

70.15

70.08

0.45

0.33

0.34

0.25

0.58

1.17

1.07

0.91

0.56

1.05

0.01

0.02

3.39

4.62

2.93

Government

0.00

28.23

28.34

29.47

29.13

28.07

28.18

24.32

26.43

Suven Life Sciences Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

Suven Life Sciences Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI